Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 3,472)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 79 news stories from 77 outlets.

Herpes is a curse for most, but may be a blessing for some. A new cancer therapy that uses a modified form of the virus to…

Herpes is a curse to most — but maybe a blessing to some. A new cancer therapy that employs a modified form of the virus to…

Herpes is a curse to most — but may a blessing to some. A new cancer therapy that employs a modified form of the virus to…

FILE PHOTO: A patient undergoes a positron emission tomography scan.Photo by Vladimir Smirnov\TASS via A new cancer therapy…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 75 additional news stories.